Factor VIII replacement therapy for hemophilia A – Hemophilia...
3 Articles
3 Articles
In Spain there are about 3,000 people with haemophilia, a disease of genetic origin in which the blood does not clot properly. Currently, there are very effective treatments that have already made people with this rare disease have the same life expectancy as the general population and much lower risk of bleeding.However, although it is not seen externally, it can still be a disease that causes certain limitations and disability.On the one hand,…
The Extraordinary Lives of Roche movement launched ‘Extraordinary Projects’, a competition that will allocate $30,000 to six initiatives of Latin American non-profit organizations that propose innovative solutions to improve the quality of life of people with hemophilia and their families, whose applications will be open until August 18. The initiative responds to a frequent reality in the region: many solutions to meet the needs of people with …
Factor VIII replacement therapy for hemophilia A – Hemophilia...
Factor VIII (FVIII) replacement therapy is a cornerstone of treatment for many people with hemophilia A, a rare bleeding disorder caused by deficient or dysfunctional FVIII, a protein needed for blood clotting. Because people with hemophilia A have reduced FVIII activity, they are prone to prolonged bleeding after injuries, surgery, or dental procedures. Those with severe disease may also experience spontaneous bleeding into joints and muscles. …
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
